

Special Issue

Alzheimer's Disease: Current Status and Future Prospects

Message from the Guest Editors

This special Edition “Alzheimer’s disease: Current State and Future Prospects” will mainly focus on the Alzheimer’s disease (AD) and its potential disease-modifying diagnostics and therapeutics that are currently being studied and advances that can be proved beneficial for patients with AD. AD is one of the major neurodegenerative disease-causing dementias and causes significant burden both physically and mentally in elderly population and their caregivers. AD is characterized by either extra cellular accumulation of amyloid beta in the form of amyloid plaques or intracellular accumulation of tau in the form of neurofibrillary tangles. Despite of several efforts to find effective ways to prevent or slowing down of disease progression, AD remains as a disease without cure. Hence the current edition mainly focuses on the diagnostic biomarkers such as tau, amyloid beta or other circulating proteins that helps in the earlier diagnosis and thereby preventing its progression. We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Guest Editors

Dr. Sireesha Manne

Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA

Dr. Naveen Kondru

Mayo Clinic, Jacksonville, FL 32224, USA

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/131247

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).